About Biomea Fusion
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 StudyGlobeNewswire Inc.Jun 5, 7:32 PM ET▲ Positive
The company presented promising clinical data showing meaningful improvements in glycemic control (1.8% HbA1c reduction) and endogenous insulin secretion in both T1D and T2D patients. Translational data demonstrated activation of beneficial metabolic pathways. The expansion of the Phase I study for BMF-650 with optimized dosing schedules indicates progress in pipeline development. No safety concerns were reported, and the data supports broader therapeutic applications beyond diabetes.
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate HighlightsGlobeNewswire Inc.May 11, 4:54 PM ET▲ Positive
Company demonstrated significant operational improvements with net losses cut by 58% year-over-year, successful completion of chronic toxicology studies enabling extended clinical dosing, positive Phase II data showing durable C-peptide preservation in type 1 diabetes patients, and multiple clinical programs progressing on schedule with key data milestones expected in 2026. However, positive sentiment is tempered by limited cash runway extending only to Q1 2027 and the early-stage nature of the programs.
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific SessionsGlobeNewswire Inc.May 5, 5:50 PM ET▲ Positive
The company announced selection of three abstracts for late-breaking poster presentations at a major diabetes conference, demonstrating clinical progress with icovamenib across multiple diabetes indications. The data showing improvements in glycemic control, C-peptide levels, and endogenous insulin secretion represents positive clinical validation of the drug candidate's mechanism and potential therapeutic benefit.
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care TherapiesGlobeNewswire Inc.Mar 31, 7:00 AM ET▲ Positive
Company achieved a significant clinical milestone by initiating two Phase II trials with first patient dosing. The trials are based on encouraging Phase II COVALENT-111 data showing durable glycemic improvements (up to 1.8% HbA1c reduction) sustained 9 months post-treatment with good safety profile. The expansion into targeted patient populations with high unmet medical needs (insulin-deficient and GLP-1 non-responders) represents meaningful clinical progress, with topline data expected in Q4 2026.
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026GlobeNewswire Inc.Mar 14, 4:30 AM ET▲ Positive
The company reported positive Phase II data showing durable efficacy of icovamenib with statistically significant HbA1c reductions in key patient populations, favorable safety profile with no serious adverse events, and clear advancement toward late-stage development with two new Phase II studies planned. The results demonstrate progress in addressing an unmet medical need in severe insulin-deficient diabetes.
